Remimazolam is an ultra-short acting benzodiazepine used intravenously for induction and maintenance of sedation for adults undergoing short term procedures not requiring general anesthesia. Remimazolam sedation has not been associated with serum aminotransferase elevations and has not been linked to cases of clinically apparent liver injury.
CITATION STYLE
DOI, M. (2014). Remimazolam. THE JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA, 34(7), 860–866. https://doi.org/10.2199/jjsca.34.860
Mendeley helps you to discover research relevant for your work.